EPCAM and breast cancer: There was a 3.4-fold and 3.1-fold increase in HPA binding of EpCAM-positive plasma-enriched sEVs from individuals with metastatic and stage 2 non-metastatic breast cancer, respectively, compared to that seen in samples from healthy individuals (p < 0.0001 and p < 0.001, respectively).